Entries of Hauschild, A. on the publication server

Gutzmer, R., Schulze, H.‐J., Hauschild, A., Leiter, U., Meier, F. , Haferkamp, S. , Ulrich, C., Wahl, R.U., Berking, C., Herbst, R., Häckl, M. and Schadendorf, D. (2021) Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS. Journal of the European Academy of Dermatology and Venereology 35 (8), pp. 1678-1685. Fulltext not available.

Livingstone, E., Eigentler, T.K. , Windemuth-Kieselbach, C., Hauschild, A., Rompel, R., Trefzer, U., Nashan, D., Kilian, K., Debus, D., Kähler, K.C., Mauerer, A., Möllenhoff, K., Dippel, E. and Schadendorf, D. (2015) Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study. British Journal of Dermatology 172 (6), pp. 1646-1650. Fulltext not available.

Oettle, H., Hilbig, A., Seufferlein, T., Tsianakas, A., Luger, T., Schmid, R. M., von Wichert, G., Endlicher, E., Garbe, C., Kaehler, K. K., Hauschild, A., Enk, A., Kiessling, P., Schmaus, S., Heinrichs, H. and Schlingensiepen, K. (2011) Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. Journal of Clinical Oncology 29 (15_sup), p. 2513. Fulltext not available.

Grob, J. J., Jouary, T., Dreno, B., Gutzmer, R., Hauschild, A., Leccia, M. T., Landthaler, M., Asselineau, J., Garbe, C. and Pehamberger, H. E. (2010) Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. Journal of Clinical Oncology 28 (18_sup), LBA8506-LBA8506. Fulltext not available.

Szeimies, R.-M., Stockfleth, E., Popp, G., Borrosch, F., Brüning, H., Dominicus, R., Mensing, H., Reinhold, U., Reich, K., Moor, A.C.E., Stocker, M., Ortland, C., Brunnert, M. and Hauschild, A. (2009) Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. British Journal of Dermatology 162 (2), pp. 410-414. Fulltext not available.

Hauschild, A., Stockfleth, E., Popp, G., Borrosch, F., Brüning, H., Dominicus, R., Mensing, H., Reinhold, U., Reich, K., Moor, A.C.E., Stocker, M., Ortland, C., Brunnert, M. and Szeimies, R.-M. (2009) Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. British Journal of Dermatology 160 (5), pp. 1066-1074. Fulltext not available.

Hauschild, A., Volkenandt, M., Tilgen, W., Linse, R., Böttjer, J., Vogt, T., Spieth, K., Eigentler, T. , Brockmeyer, N. H. and Weichenthal, M. (2008) Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial. Journal of Clinical Oncology 26 (15_sup), p. 9032. Fulltext not available.

Schadendorf, D., Hauschild, A., Ugurel, S., Thoelke, A., Egberts, F., Kreissig, M., Linse, R., Trefzer, U., Vogt, T., Tilgen, W., Mohr, P. and Garbe, C. (2006) Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Annals of Oncology 17 (10), pp. 1592-1597. Fulltext not available.